Qualification: 
M. Pharm., B. Pham.
merinb@aims.amrita.edu

Merin Babu, joined in Department of Pharmacology, Amrita School of Pharmacy in June 2017. She has around one year experience in teaching and research. She was working as Lecturer in the Dale View College of Pharmacy and Research Centre, Trivandrum. She completed B.Pharm and M.Pharm from Amrita Vishwa Vidyapeetham in 2010 and 2016 respectively.

Publications

Publication Type: Journal Article

Year of Publication Publication Type Title

2017

Journal Article

Merin Babu and Jacob, L. M., “A rare case report on pulmonary hamartoma”, Journal of Pharmaceutical Sciences and Research, vol. 9, pp. 1559-1560, 2017.[Abstract]


Hamartomas are non-neoplastic malformations which can be observed in lungs, pancreas, spleen, liver and kidney. Here, we have reported a 43 year old female on treatment for hypothyroidism was presented with complaints of dyspnea. The patient had undergone thyroidectomy 10 years ago. Her chest X-ray showed a solitary pulmonary nodule. The nodule size remained in the size range of 3-4cm. The diagnosis of solitary pulmonary nodule is only to undergo conservative surgery to remove the nodule. © 2017, Pharmainfo Publications. All rights reserved.

More »»

2017

Journal Article

Merin Babu, Menon, V. P., and Dr. Umadevi P., “Epidemiology and outcome among severe sepsis and septic shock patients in a South Indian tertiary care hospital”, International Journal of Pharmacy and Pharmaceutical Sciences, vol. 9, p. 256, 2017.[Abstract]


Objective: The objective of this research was to determine the prevalence of severe sepsis and septic shock and evaluate its outcome.Methods: This was a prospective, observational study, in which adult patients with severe sepsis or septic shock were included. Relevant information was collected from medical records and the hospital information system.Results: A total of 250 patients [mean age 57.2 y (range: 18 to 98 y)] was studied. The majority of the patients suffered from severe sepsis (81.2%). Most of the episodes occurred in males (75.2%). Major comorbidities included diabetes mellitus (51.2%), hypertension (44.8%) and chronic liver disease (30.4%). One hundred and seventy-eight patients (147 patients with severe sepsis and 31 patients with septic shock) had a positive culture with urine being the main site of infection. One hundred and two patients (40.8%) had a monomicrobial infection while seventy-six (30.4%) patients had a polymicrobial infection. Within the monomicrobial infections, the gram negative organisms predominated (54%). The mean hospital stay for patients with severe sepsis was 11.5 d. Mortality was noted in 79 patients (40 patients with septic shock and 39 patients with severe sepsis).Conclusion: The main causative pathogens were gram negative bacteria. Admissions meeting septic shock criteria have a high mortality rate. Hence, it is imperative to identify patients who are at high risk and treat them promptly to reduce serious consequences.

More »»

2017

Journal Article

Merin Babu and J., J. C., “Rucaparib: a PARP inhibitor for the treatment of advanced ovarian cancer”, International Journal of Basic & Clinical Pharmacology, vol. 6, p. 1018, 2017.[Abstract]


Ovarian cancers arise from the uncontrolled growth and replication of epithelial cells of the surface of ovary which constitutes 90% of cases. PARP (poly ADP-ribose polymerase) inhibitors are a novel type of therapy that prevents cancer cells from repairing their DNA which have been damaged by other chemotherapeutic agents. Rucaparib is a novel drug that was approved by the US FDA in 2016 for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer. Inhibition of the PARP enzymes leads to the increased formation of PARP-DNA complexes which results in DNA damage, apoptosis and cell death. Nausea, fatigue including asthenia, vomiting, anemia, abdominal pain, constipation, decreased appetite, diarrhea, thrombocytopenia and dyspnea were the common adverse effects seen among rucaparib users. Even though, the drug may cause myleodysplastic syndrome/ acute myeloid leukemia (MDS/AML) it remains as novel therapeutic target for the treatment of advanced ovarian cancer involving BRCA mutation.

More »»

2017

Journal Article

S. Stephen, Markkassery, R., Sainudheen, B. Edathuruth, Merin Babu, Balakrishnan, D., Sudhindran, S., and Padma, U. Devi, “A Comparative Study of Once Daily Versus Twice Daily Tacrolimus in Liver Transplantation”, Journal of Young Pharmacists, vol. 9, pp. 605-609, 2017.[Abstract]


Once daily (OD) tacrolimus, recently launched for post liver transplant immunosuppression might offer better compliance and efficacy compared to standard twice daily (BID) tacrolimus. Data from India, however is sparse. Aim: The aim of our study was to compare the efficacy and adverse effects of OD versus BID tacrolimus formulation in liver transplant recipients. Methods: This was a retrospective, observational, comparative study of 115 patients who were on tacrolimus based regimens (tacrolimus BID: 92; M: F-75:17 and tacrolimus OD: 23; M: F-22:1). Total daily dose and trough levels of tacrolimus were recorded at 1, 3, 6, 12 and 24 months after transplantation. Results: Median age in tacrolimus BID and OD groups were 45 years (6-64 years) and 50 years (1-70 years), respectively. The median tacrolimus dose was significantly lower in the tacrolimus OD arm at all the time points studied. Tacrolimus trough levels were significantly lower in the tacrolimus OD group at 3 and 6 months. The biopsy proven rejection rate was 15.2% and 0% in the tacrolimus BID and OD groups, respectively. Two year patient and graft survival rate was 89.4% in the tacrolimus BID and 87.5% in the tacrolimus OD group. The incidence of new onset diabetes, renal dysfunction, dyslipidemia, neurotoxicity, hyperkalemia and weight gain were comparable between the two arms. Conclusion: Tacrolimus OD has a lower rejection rate compared to its BID formulation. However, this does not translate into better patient or graft survival. Both the formulations appear to be comparable with respect to the adverse effect and tolerability profile.

More »»
207
PROGRAMS
OFFERED
6
AMRITA
CAMPUSES
15
CONSTITUENT
SCHOOLS
A
GRADE BY
NAAC, MHRD
8th
RANK(INDIA):
NIRF 2018
150+
INTERNATIONAL
PARTNERS
  • Amrita on Social Media

  • Contact us

    Amrita Vishwa Vidyapeetham
    Amritanagar, Coimbatore - 641 112
    Tamilnadu, India
    • Fax: +91-422-2686274
    • Coimbatore : +91 (422) 2685000
    • Amritapuri   : +91 (476) 280 1280
    • Bengaluru    : +91 (080) 251 83700
    • Kochi              : +91 (484) 280 1234
    • Mysuru          : +91 (821) 234 3479
    • Contact Details »